02.10.2014 Views

Back Matter - The Journal of Bone & Joint Surgery

Back Matter - The Journal of Bone & Joint Surgery

Back Matter - The Journal of Bone & Joint Surgery

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

Are safety considerations limiting your use <strong>of</strong> ibupr<strong>of</strong>en?<br />

It’s time to set the story straight<br />

Take a closer look before your next OTC analgesic recommendation<br />

Data and messages around OTC analgesics continue to evolve, and, therefore, treatment paradigms must evolve<br />

as well. Take another look, and you may find that some communications are not telling the full story. When<br />

considering which OTC analgesic to recommend, it is important to periodically review all the evidence on risks<br />

and benefits as the data set continues to grow.<br />

OTC ibupr<strong>of</strong>en may be right for more patients than you think*<br />

• Clinical studies have shown when OTC ibupr<strong>of</strong>en<br />

is taken as directed by the label for no longer<br />

than 10 days, there is a very low increased risk<br />

<strong>of</strong> stomach complaints or bleeding 1-4<br />

• In a study by Moore et al, GI tolerability <strong>of</strong><br />

OTC ibupr<strong>of</strong>en was at least as favorable as<br />

acetaminophen during 7-day therapy 5<br />

• Studies have demonstrated that higher doses<br />

<strong>of</strong> ibupr<strong>of</strong>en are associated with a greater risk<br />

<strong>of</strong> GI side effects (odds ratio 4.6) vs lower<br />

(OTC) doses (odds ratio 1.1) 1,6<br />

• Naproxen and OTC ibupr<strong>of</strong>en have the<br />

most favorable cardiovascular risk pr<strong>of</strong>ile<br />

among widely used Rx and OTC NSAIDs 7<br />

• For patients already on, or for whom you<br />

are considering initiating a cardioprotective<br />

aspirin regimen:<br />

– Taking ibupr<strong>of</strong>en at least ½ hour after the<br />

dosing <strong>of</strong> immediate-release low-dose<br />

aspirin is a practical method to minimize<br />

potential impairment <strong>of</strong> the antiplatelet<br />

effect <strong>of</strong> aspirin 8,9<br />

– Because the effect <strong>of</strong> aspirin taken<br />

daily on platelets is long lasting, the<br />

occasional use <strong>of</strong> ibupr<strong>of</strong>en poses<br />

a minimal risk <strong>of</strong> attenuating the<br />

antiplatelet effect <strong>of</strong> low-dose aspirin 9<br />

• Overall, OTC ibupr<strong>of</strong>en has a low risk<br />

factor for developing acute or chronic<br />

renal conditions 1,10,11<br />

• NSAIDs, including ibupr<strong>of</strong>en, demonstrate an<br />

increased risk <strong>of</strong> causing renal impairment<br />

at high (Rx) doses, especially among elderly<br />

patients or patients with reduced renal function 12<br />

• OTC ibupr<strong>of</strong>en has a very low risk factor for<br />

developing liver injury, especially compared<br />

to the severe liver damage observed with<br />

acetaminophen overdose and the occasional<br />

liver reaction from aspirin 1,2<br />

• A large-scale review article concluded that,<br />

when compared with all analgesics, OTC<br />

ibupr<strong>of</strong>en is less toxic in serious overdose<br />

situations and is rarely associated with deaths<br />

from either accidental or intentional overdose<br />

(or with serious adverse events) 1<br />

* Remind patients to use OTC analgesics as directed.<br />

Nothing is more effective than Advil ® for acute pain. †13-17 Rethink Relief. Think Advil ® .<br />

†<br />

Among leading OTC pain relievers/fever reducers.<br />

To get a closer look at the clinical evidence and the Advil ® label, please visit us at www.AdvilAide.com.<br />

We invite you to explore the latest data on ibupr<strong>of</strong>en in regard to GI tolerability; cardiovascular, renal,<br />

and hepatic safety; as well as toxicity. What you fi nd may surprise you.<br />

References: 1. Rainsford KD. Ibupr<strong>of</strong>en: pharmacology, effi cacy, and safety. Infl ammopharmacology. 2009;17(6):275-342. 2. Rainsford KD, Roberts C, Brown S. Ibupr<strong>of</strong>en and<br />

paracetamol: relative safety in non-prescription dosages. J Pharm Pharmacol. 1997;49:365-376. 3. Kellstein DE, Waksman JA, Furey SA, Binstok G, Cooper SA. <strong>The</strong> safety pr<strong>of</strong>i le <strong>of</strong><br />

nonprescription ibupr<strong>of</strong>en in multiple-dose use: a meta-analysis. J Clin Pharmacol. 1999;39:520-532. 4. Bjarnason I. Ibupr<strong>of</strong>en and gastrointestinal safety: a dose-duration-dependent<br />

phenomenon. J R Soc Med. 2007;100(suppl 48):11-14. 5. Moore N, Van Ganse E, Le Parc J-M, et al. <strong>The</strong> PAIN study: paracetamol, aspirin and ibupr<strong>of</strong>en new tolerability study. Clin<br />

Drug Invest. 1999;18(2):89-98. 6. Lewis SC, Langman MJS, Laporte J-R, Matthews JNS, Rawlins MD, Wiholm B-E. Dose-response relationships between individual nonaspirin<br />

nonsteroidal anti-infl ammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data. Br J Clin Pharmacol. 2002;54(3):320-326.<br />

7. McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-infl ammatory drugs: systematic review <strong>of</strong> population-based controlled observational studies. PLoS Med.<br />

2011;8(9):1-18. doi:10.1371/journal.pmed.1001098. 8. Cryer B, Berlin RG, Cooper SA, Hsu C, Wason S. Double-blind, randomized, parallel, placebo-controlled study <strong>of</strong> ibupr<strong>of</strong>en<br />

effects on thromboxane B 2 concentrations in aspirin-treated healthy adult volunteers. Clin <strong>The</strong>r. 2005;27(2):185-191. 9. Food and Drug Administration science paper: concomitant<br />

use <strong>of</strong> ibupr<strong>of</strong>en and aspirin: potential for attenuation <strong>of</strong> the anti-platelet effect <strong>of</strong> aspirin. Food and Drug Administration Web site. http://www.fda.gov/downloads/Drugs/DrugSafety/<br />

PostmarketDrugSafetyInformationforPatientsandProviders/UCM161282.pdf. Published September 8, 2006. Accessed June 6, 2012.10. Whelton A. Renal effects <strong>of</strong> over-the-counter<br />

analgesics. J Clin Pharmacol. 1995;35:454-463. 11. Furey SA, Vargas R, McMahon FG. Renovascular effects <strong>of</strong> nonprescription ibupr<strong>of</strong>en in elderly hypertensive patients with mild renal<br />

impairment. Pharmacotherapy. 1993;13(2):143-148. 12. Kean WF, Rainsford KD, Kean IRL. Management <strong>of</strong> chronic musculoskeletal pain in the elderly: opinions on oral medication use.<br />

Infl ammopharmacology. 2008;16:53-75. 13. Data on fi le. Pfi zer Consumer Healthcare. 14. Bradley JD, Brandt KD, Katz BP, Kalasinski LA, Ryan SI. Comparison <strong>of</strong> an antiinfl ammatory<br />

dose <strong>of</strong> ibupr<strong>of</strong>en, an analgesic dose <strong>of</strong> ibupr<strong>of</strong>en, and acetaminophen in the treatment <strong>of</strong> patients with osteoarthritis <strong>of</strong> the knee. N Engl J Med. 1991;325:87-91. 15. Dalton JD Jr,<br />

Schweinle JE. Randomized controlled noninferiority trial to compare extended release acetaminophen and ibupr<strong>of</strong>en for the treatment <strong>of</strong> ankle sprains. Ann Emerg Med. 2006;48:<br />

615-623. 16. Boureau F, Schneid H, Zeghari N, Wall R, Bourgeois P. <strong>The</strong> IPSO study: ibupr<strong>of</strong>en, paracetamol study in osteoarthritis: a randomised comparative clinical study comparing<br />

the effi cacy and safety <strong>of</strong> ibupr<strong>of</strong>en and paracetamol analgesic treatment <strong>of</strong> osteoarthritis <strong>of</strong> the knee or hip. Ann Rheum Dis.2004;63:1028-1034. 17. Schiff M, Minic M. Comparison <strong>of</strong><br />

the analgesic effi cacy and safety <strong>of</strong> nonprescription doses <strong>of</strong> naproxen sodium and ibupr<strong>of</strong>en in the treatment <strong>of</strong> osteoarthritis <strong>of</strong> the knee. J Rheumatol. 2004;31:1373-1383.<br />

©2012 Pfi zer Inc. 06/12<br />

ADV051254<br />

AdvilAide.com<br />

Downloaded From: http://jbjs.org/ on 01/27/2014

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!